Canada markets closed

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0185+0.0015 (+8.82%)
At close: 02:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0170
Open0.0170
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0160 - 0.0200
52 Week Range0.0160 - 0.0560
Volume224,876
Avg. Volume267,946
Market Cap7.166M
Beta (5Y Monthly)-0.21
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateMay 28, 2024 - Jun 03, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

    TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request for the evaluation of a proposed clinical study of Bucillamine, an ora

  • GlobeNewswire

    Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

    TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on

  • GlobeNewswire

    Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

    TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an invest